Sulforaphane inhibits endothelial protein C receptor shedding in vitro and in vivo

Vascular Pharmacology

Volumn 63, Issue 1, 2014, Pages 13-18

  Ku, Sae Kwang ^a   Han, Min Su ^b   Bae, Jong Sup ^c  

^a Daegu Haany University   (South Korea)

^b Daegu Fatima Hospital   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

EPCR shedding; Sulforaphane; Vascular inflammation

Indexed keywords

ENDOTHELIAL PROTEIN C RECEPTOR; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHORBOL 13 ACETATE 12 MYRISTATE; STRESS ACTIVATED PROTEIN KINASE; SULFORAPHANE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ACTIVATED PROTEIN C RECEPTOR; ADAM PROTEIN; BLOOD CLOTTING FACTOR; CELL SURFACE RECEPTOR; ISOTHIOCYANIC ACID DERIVATIVE; SULFORAFAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURFACE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEPTICEMIA; VASCULITIS; ANIMAL; C57BL MOUSE; CECUM; DISEASE MODEL; DRUG EFFECTS; INJURIES; METABOLISM; PATHOPHYSIOLOGY; SEPSIS; UMBILICAL VEIN ENDOTHELIAL CELL;

ADAM PROTEINS; ANIMALS; BLOOD COAGULATION FACTORS; CECUM; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-1BETA; ISOTHIOCYANATES; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CELL SURFACE; SEPSIS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908049579     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.06.002     Document Type: Article

References (28)

1. Bae J.S., Rezaie A.R. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 2011, 118:3952-3959.
2. Borgel D., Bornstain C., Reitsma P.H., Lerolle N., Gandrille S., Dali-Ali F., et al. A comparative study of the protein C pathway in septic and nonseptic patients with organ failure. Am J Respir Crit Care Med 2007, 176:878-885.
3. Buras J.A., Holzmann B., Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov 2005, 4:854-865.
4. Fahey J.W., Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol 1999, 37:973-979.
5. Fulcher C.A., Gardiner J.E., Griffin J.H., Zimmerman T.S. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984, 63:486-489.
6. Han H., Du B., Pan X., Liu J., Zhao Q., Lian X., et al. CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Mol Cancer Res 2010, 8:1477-1488.
7. Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001, 276:32008-32015.
8. Huovila A.P., Turner A.J., Pelto-Huikko M., Karkkainen I., Ortiz R.M. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005, 30:413-422.
9. Jeong G.S., Lee D.S., Kim Y.C. Cudratricusxanthone A from Cudrania tricuspidata suppresses pro-inflammatory mediators through expression of anti-inflammatory heme oxygenase-1 in RAW264.7 macrophages. Int Immunopharmacol 2009, 9:241-246.
10. Killeen M.E., Englert J.A., Stolz D.B., Song M., Han Y., Delude R.L., et al. The phase 2 enzyme inducers ethacrynic acid, DL-sulforaphane, and oltipraz inhibit lipopolysaccharide-induced high-mobility group box 1 secretion by RAW 264.7 cells. J Pharmacol Exp Ther 2006, 316:1070-1079.
11. Kim D.C., Lee W., Bae J.S. Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. Inflamm Res 2011, 60:1161-1168.
12. Kremer J.P., Jarrar D., Steckholzer U., Ertel W. Interleukin-1, -6 and tumor necrosis factor-alpha release is down-regulated in whole blood from septic patients. Acta Haematol 1996, 95:268-273.
13. Kurosawa S., Stearns-Kurosawa D.J., Carson C.W., D'Angelo A., Della Valle P., Esmon C.T. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998, 91:725-727.
14. Kurosawa S., Stearns-Kurosawa D.J., Hidari N., Esmon C.T. Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 1997, 100:411-418.
15. Leng Y., Steiler T.L., Zierath J.R. Effects of insulin, contraction, and phorbol esters on mitogen-activated protein kinase signaling in skeletal muscle from lean and ob/ob mice. Diabetes 2004, 53:1436-1444.
16. Liaw P.C., Neuenschwander P.F., Smirnov M.D., Esmon C.T. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000, 275:5447-5452.
17. Lin W., Wu R.T., Wu T., Khor T.O., Wang H., Kong A.N. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol 2008, 76:967-973.
18. Menschikowski M., Hagelgans A., Eisenhofer G., Siegert G. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Exp Cell Res 2009, 315:2673-2682.
19. Michie H.R., Manogue K.R., Spriggs D.R., Revhaug A., O'Dwyer S., Dinarello C.A., et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988, 318:1481-1486.
20. Miller M.A., Meyer A.S., Beste M.T., Lasisi Z., Reddy S., Jeng K.W., et al. ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc Natl Acad Sci U S A 2013, 110:E2074-E2083.
21. Mosnier L.O., Zlokovic B.V., Griffin J.H. The cytoprotective protein C pathway. Blood 2007, 109:3161-3172.
22. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008, 8:929-941.
23. Qu D., Wang Y., Esmon N.L., Esmon C.T. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. J Thromb Haemost 2007, 5:395-402.
24. Qu D., Wang Y., Song Y., Esmon N.L., Esmon C.T. The Ser219-Gly dimorphism of the endothelial protein C receptor contributes to the higher soluble protein levels observed in individuals with the A3 haplotype. J Thromb Haemost 2006, 4:229-235.
25. Thalhamer T., McGrath M.A., Harnett M.M. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:409-414.
26. Wang H., Liao H., Ochani M., Justiniani M., Lin X., Yang L., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221.
27. Xu J., Qu D., Esmon N.L., Esmon C.T. Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 2000, 275:6038-6044.
28. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296-301.